Paliperidone ER: A review of the clinical trial data

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 6, 2007, Pages 869-883

  Janicak, Philip G ^a   Winans, Elizabeth A ^b,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Shane Creado   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Antipsychotic; Extended release; Paliperidone; Schizophrenia

Indexed keywords

AMIODARONE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GATIFLOXACIN; LORAZEPAM; MOXIFLOXACIN; NEUROLEPTIC AGENT; OLANZAPINE; OROS DELIVERY SYSTEM; PALIPERIDONE; PLACEBO; PROCAINAMIDE; QUETIAPINE; QUINIDINE; RISPERIDONE; SOTALOL; THIORIDAZINE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

AGGRESSION; AGITATION; AKATHISIA; AMENORRHEA; ANORGASMIA; ANXIETY; AREA UNDER THE CURVE; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ELDERLY CARE; EMBASE; EXTRAPYRAMIDAL SYMPTOM; FOOD; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HUMAN; HYPERKINESIA; IMPOTENCE; INSOMNIA; INSULIN BLOOD LEVEL; LACTATION; LIBIDO DISORDER; LIPID BLOOD LEVEL; LIVER METABOLISM; LONG TERM CARE; MAINTENANCE THERAPY; MEDLINE; MOTOR DYSFUNCTION; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RESTLESSNESS; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL INTERACTION; SOMNOLENCE; STEADY STATE; SUICIDE ATTEMPT; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; TREATMENT DURATION; TREMOR; WEIGHT CHANGE; WEIGHT GAIN;

EID: 38349057515     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Canuso C, Bossie C, Turkoz I, et al. 2006a. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Int J Neuropsychopharmacol, 9:S280.
2. Canuso C, Youssef E, Dirks B, et al. 2006b. Paliperidone extended-release in severely ill patients with schizophrenia. Presented at the Institute on Psychiatric Services, October 5-8 2006, New York, NY, USA.
3. Canuso C, Youssef E, Bossie C, et al. 2007, Effects of paliperidone ER in patients with schizophrenia previously treated with risperidone. Presented at the International Congress on Schizophrenia Research, 28 March-1 April 2007, Colorado Springs, CO, USA.
4. Carney C, Jones L, Woolson RF. 2006. Medical comorbidity in women and men with schizophrenia. J Gen Intern Med, 21:1133-7.
5. Conley R, Gupta SK, Sathyan G. 2006. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS®), an advanced oral delivery form. Curr Med Res Opin, 22:1879-92.
6. Davidson M, Emsley R, Kramer M et al. 2007. Efficacy, safety and effect on functioning of paliperidone extended-release tablets in the treatment of acute schizophrenia: an international 6-week placebo-controlled study. Schizophrenia Res, 93:117-30.
7. Dirks B, Eerdekens M, Turkoz I, et al. 2006. Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms. Int J Neuropsychopharmacol, 9:S162.
8. Dirks B, Youssef E, Bossie C, et al. 2007. Effects of paliperidone ER in patients with schizophrenia previously treated with olanzapine. Presented at the International Congress on Schizophrenia Research, March 28-April 12007, Colorado, USA.
9. Eerdekens M, Kramer M, Lane R, et al. 2007 Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 52-week, open-label extension studies. Poster presented at the International Congress on Schizophrenia Research, March 28-April 1 2007, Colorado Springs, CO, USA. Poster number: 290.
10. Guy W. 1976. Clinical Global Impressions Scale. ECDEU Assessment manual. 218-22.
11. Hough D, Kramer M, Cleton A, et at. 2007. A randomized, double-blind, placebo-controlled, parallel-group study evaluating QT/QTC intervals following administration of paliperidone ER and quetiapine in patients with schizophrenia or schizoaffective disorder. Presented at Society of Biological Psychiatry, May 17-19 2007, San Diego, CA, USA. Poster number: 858.
12. INVEGA package insert. 2007. Prescribing information for paliperidone extended-release [online]. Accessed June 2007. URL: http://wwwjanssen.com/active/janus/en_US/assets/common/company/pi/ invega.pdf;jsessionid=3HLH4CUHTOA0UCQPCCFTC0YKB2IIQNSC.
13. Janicak P, Davis J, Preskorn S, et al. 2006. Principles and Practice of Psychopharmacotherapy. 4th ed. Philadelphia: Lippincott Williams and Wilkins. p 81-182.
14. Kane J, Canas F, Kramer M, et al. 2007. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Res, 90:147-61.
15. Knegtering R, Baselmans P, Castelein S, et al. 2005. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry, 162:1010-2.
16. Kostic D, Bossie C, Turkoz I. 2006a. Paliperidone extended-release tablets in patients recently diagnosed with schizophrenia. Presented at Collegium Internationale Neuro-Psychopharmacologicum, July 9-13 2006, Chicago, IL, USA.
17. Kostic D, Bossie C, Turkoz I, et al. 2006b. Paliperidone extended-release tablets in patients recently diagnosed with schizophrenia. Int J Neuropsychopharmacol, 9:S161.
18. Kramer M, Kushner S, Vijapurkar U, 2006. Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablet: an international, randomized, double-blind, placebo-controlled study. Presented at the Collegium Internationale Neuro-Psychopharmacologicum, July 9-13 2006, Chicago, IL, USA.
19. Kramer M, Kushner S, Vijapurkar U. 2007a. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol, 27:6-14.
20. Kramer M, Eerdekens M, Lane R, et al. 2007b. Metabolic outcomes, in terms of weight, glucose and lipid profiles, in patients with schizophrenia treated with paliperidone extended-release tablets for 52 weeks. Presented at the American Psychiatric Association Annual Meeting, May 19-24 2007, San Diego, CA, USA. Poster number: NR498.
21. Luthringer R, Staner L, Noel N. 2007. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharm, 22:299-308.
22. Marder SR, Kramer M,, Ford L, et al. 2007. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry, June 27; [Epub ahead of print] doi: 10.1016/j.biopsych.2007.01.017.
23. Marder SR, Davis JM, Chouinard G. 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry, 58:538-46.
24. Melkersson KI. 2006. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol, 21:529-32.
25. Meltzer H, Kramer M, Gassmann-Mayer C, et al. 2006. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo controlled studies. Int J Neuropsychopharmacol, 9:S225.
26. Meyer J, Kramer M, Lane R, et al. 2006. Metabolic outcomes in patients with schizophrenia treated with oral paliperidone extended-release tablets: pooled analysis of three 6-week placebo-controlled studies. Int J Neuropsychopharmacol, 9:S282.
27. Morosini PL, Magliano L, Brambilla L. 2000. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand, 101:323-9.
28. Patrick D, Adriaenssen I, Morosini P, et al. 2006. Reliability, validity and sensitivity to change of the personal and social performance scale in patients with acute schizophrenia. Int J Neuropsychopharmacol, 9: S287-88.
29. Rosen H, Abribat T. 2005. The rise and rise of drug delivery. Nat Rev Drug Discov, 4:381-5.
30. Rossenu S, Cleton A, Talluri K, et al. 2007. Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone with an immediate-release formulation of risperidone. Clin Pharm Ther, 81(Suppl 1):S62.
31. Rossenu SAC, Rusch S, Janssens S, et al. 2006. Extended-release formulation of paliperidone shows dose proportional pharmacokinetics. Presented at the American Association of Pharmaceutical Sciences Annual Meeting and Exposition, October 29-November 2 2006, San Antonio, TX, USA. Poster number: T3123.
32. Schooler N, Gharabawi G, Bossie C, et al. 2006. A virtual comparison of paliperidone ER and oral risperidone in patients with schizophrenia. Presented at the 45th Annual Meeting of the American College of Neuropharmacology, December 3-7 2006, Hollywood, FL, USA.
33. Thyssen A, Cleton A, Osselae NV. 2007. Effects of renal impairment on the pharmacokinetic profile of paliperidone extended-release tablets. Clin Pharm Ther, 81(Suppl 1): S63.
34. Thyssen A, Cleton A, Talluri K, 2006a. Absence of pharmacokinetic; interaction between trimethoprim and paliperidone extended-release tablets in healthy subjects. Biol Psychiatry, 59:181-64.
35. Thyssen A, Crauwels H, Cleton A, et al. 2006b. Effects of hepatic impairment on the pharmacokinetics of paliperidone immediate-release. Presented at the 46th New Clinical Drug Evaluation Unit Annual Meeting, June 12-15 2006, Boca Raton, FL, USA.
36. Tzimos A, Samokhvalov V, Kramer M, et al. 2007. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: A double-blind, placebo-controlled study with long-term open-label extension. Am J Geriatric Psych, in press.
37. Vermeir M, Boom S, Naessens I, et al. 2005. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur Neuropsychopharmacol, 30:S191-92.
38. Zhou Z, Li X, Peng H, et al. 2006. Predominant role of the 9-hydroxy metabolite of risperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin, 27:381-6.